个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study

| 导出 | |

文献详情

资源类型：
Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ 卓越：领军期刊 ◇ 中华系列

作者：
Shi Yuequan[1,2] * ; Liu Xiaoyan[1] ; Liu Anwen[3] ; Fang Jian[4] ; Meng Qingwei[5] ; Ding Cuimin[6] ; Ai Bin[7] ; Gu Yangchun[8] ; Zhang Cuiying[9] ; Zhou Chengzhi[10] ; Wang Yan[11] ; Shui Yongjie[12] ; Yu Siyuan[1] ; Zhang Dongming[1] ; Liu Jia[1] ; Zhang Haoran[1] ; Zhou Qing[1] ; Gao Xiaoxing[1] ; Chen Minjiang[1] ; Zhao Jing[1] ; Zhong Wei[1] ; Xu Yan[1] ; Wang Mengzhao[1] ;
机构： [1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. [2]Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. [3]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi 330006, China. [4]Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China. [5]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China. [6]Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050033, China. [7]Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100005, China. [8]Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China. [9]Department of Medical Oncology, Cancer Center, People's Hospital, Hohhot, Inner Mongolia Autonomous Region 750306, China. [10]Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510120, China. [11]Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China. [12]Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
出处：
DOI： 10.1097/CM9.0000000000003620
ISSN：

关键词： Non-small cell lung cancer Programmed cell death-1/programmed cell death-ligand 1 Tumor proportional score Prognosis Immune-related adverse events

摘要：
This study aimed to investigate the safety and efficacy of programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) antibody-based therapy in treating patients with advanced non-small cell lung cancer (NSCLC) according to different PD-L1 expression statuses in a real-world setting.This retrospective, multicenter, observational study enrolled adult patients who received PD-1/PD-L1 antibody-based therapy in China and met the following criteria: (1) had pathologically confirmed, unresectable stage III-IV NSCLC; (2) had a baseline PD-L1 tumor proportion score (TPS); and (3) had confirmed efficacy evaluation results after PD-1/PD-L1 treatment. Logistic regression, Kaplan-Meier analysis, and Cox regression were used to assess the progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAEs) as appropriate.A total of 409 patients, 65.0% (n = 266) with a positive PD-L1 TPS (≥1%) and 32.8% (n = 134) with PD-L1 TPS ≥50%, were included in this study. Cox regression confirmed that patients with a PD-L1 TPS ≥1% had significantly improved PFS (hazard ratio [HR] 0.747, 95% confidence interval [CI] 0.573-0.975, P = 0.032). A total of 160 (39.1%) patients experienced 206 irAEs, and 27 (6.6%) patients experienced 31 grade 3-5 irAEs. The organs most frequently associated with irAEs were the skin (52/409, 12.7%), thyroid (40/409, 9.8%), and lung (34/409, 8.3%). Multivariate logistic regression revealed that a PD-L1 TPS ≥1% (odds ratio [OR] 1.713, 95% CI 1.054-2.784, P = 0.030) was an independent risk factor for irAEs. Other risk factors for irAEs included pretreatment absolute lymphocyte count >2.5 × 109/L (OR 3.772, 95% CI 1.377-10.329, P = 0.010) and pretreatment absolute eosinophil count >0.2 × 109/L (OR 2.006, 95% CI 1.219-3.302, P = 0.006). Moreover, patients who developed irAEs demonstrated improved PFS (13.7 months vs. 8.4 months, P <0.001) and OS (28.0 months vs. 18.0 months, P = 0.007) compared with patients without irAEs.A positive PD-L1 TPS (≥1%) was associated with improved PFS and an increased risk of irAEs in a real-world setting. The onset of irAEs was associated with improved PFS and OS in patients with advanced NSCLC receiving PD-1/PD-L1-based therapy.Copyright © 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金：
This study is funded by a grant from the National High Level Hospital Clinical Research Funding to Wei Zhong, grant number 2022-PUMCH-C-054.
语种：
外文
PubmedID：
中科院分区：
出版当年[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：内科
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：内科
第一作者：
第一作者机构： [1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. [2]Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Shi Yuequan,Liu Xiaoyan,Liu Anwen,et al.Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study[J].Chinese Medical Journal.2025,doi:10.1097/CM9.0000000000003620.
APA：
Shi Yuequan,Liu Xiaoyan,Liu Anwen,Fang Jian,Meng Qingwei...&Wang Mengzhao.(2025).Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.Chinese Medical Journal,,
MLA：
Shi Yuequan,et al."Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study".Chinese Medical Journal .(2025)

相关文献

[1]PD-1/PD-L1抑制剂在食管癌治疗中的进展 [2]PD-L1 expression is associated with advanced non-small cell lung cancer [3]MicroRNA-142-5p Suppresses Proliferation and Invasion of Non-Small Cell Lung Cancer Cells by Targeting Programmed Cell Death Receptor Ligand 1 [4]Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study [5]Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) [6]Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers [7]Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmod Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer [8]Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation [9]Yin Yang 1-stimulated long noncoding RNA bladder cancer-associated transcript 1 upregulation facilitates esophageal carcinoma progression via the microRNA-5590-3p/programmed cell death-ligand 1 pathway [10]程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展

资源点击量：42313 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号